Perseus, L.L.C. Funds
 


THE PERSEUS FUNDS

erseus 1996 was an investment program established in 1996 that invested $35 million in undervalued and growth equity transactions. This program is fully invested.

Perseus Capital, L.L.C. was established in 1997 with $102 million in capital commitments to make growth equity investments and some venture investments with a focus on information-based companies, undervalued industrial and commercial companies, and biotechnology investments. This fund is fully invested.

Perseus Acquisition/Recapitalization Fund, L.L.C. was established in 1999 to identify, structure, and execute larger leveraged buyouts, recapitalizations, or similar investments, frequently on a co-investment basis, alongside other Perseus funds. The fund called $98 million in capital commitments. This fund has reached its termination date and is no longer making investments.

Perseus 2000, L.L.C. was established in 2000 with $222 million in capital commitments to focus on undervalued growth equity, small buyout, and venture opportunities in various industries, including energy, environmental, and engineering technology and healthcare sectors, and content-based companies. This fund is fully invested.

Perseus Market Opportunity Fund, L.P. was established in 2002 with $340 million of committed capital to pursue control investments in undervalued growth equity companies and turnaround situations as well as to identify opportunities in publicly traded companies. This fund is fully invested.

Perseus 2000 Expansion, L.L.C., which was established in 2004, is a $153 million fund used primarily for follow-on investments in undervalued growth equity, small buyout, and venture opportunities in various industries, including the energy, environmental, and engineering technology and healthcare sectors as well as content-based companies. This fund is fully invested.

Perseus Partners VII, L.P., which was established in 2006, is a $602 million fund focused on control investments in middle market growth equity transactions principally in the energy, environmental, and engineering technology, healthcare, and branded consumer products sectors. This fund has been fully committed or reserved.

PERSEUS-SOROS BIOPHARMACEUTICAL FUND, LP, which was established in 2000 with $449 million in capital commitments, focused on investments in life science companies developing biopharmaceutical products and/or creating businesses based on advanced life science technologies. This fund is managed by a separate executive team, the senior executives of which were recruited at the time of the fund’s formation by Perseus and its co-manager. This fund is fully invested or reserved.

Updated 6/26/12

Boetian relief pithos
 



 

In an early Greek depiction, Medusa appears with the body of a horse. Bulging eyes, flattened nose and prominent teeth, rather than the more customary serpents for hair, are primary elements in her fearsome appearance. Perseus prudently averts his eyes as he strikes the fatal blow.

Boetian relief pithos, detail of neck, early 7th century B.C. Terracotta, h. 130 cm. Louvre Museum, Paris

 


© 2001-12 PERSEUS, L.L.C., Designer: Beebe Comm. Updated 6/26/12
Photo Credits: Bridgeman Art Library and Art Resource.